SBIR/STTR Research Award

Discriminating Drug Safety Profiles in Polytherapy

Award identifier 09278d4deda7526799c0f57ac3e1bae34c19b93e48c66f02f9746cc2eba4c5f3Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$714,138

Program and phase

SBIR · Phase II

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CAPITAL TECHNOLOGY INFORMATION SERVICES,
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Statistical data mining applied to large databases of spontaneous post-marketing adverse event reports has demonstrated substantial utility in supporting pharmacovigilance efforts at government health authorities and pharmaceutical manufacturers. The goal of this project is to develop and validate advanced statistical methods for assessing the true association strengths between specific drugs and specific events, accounting for significant polytherapy within and across individual reports. These methods will support generating more accurate drug safety profiles that are corrected for confounding induced by the presence of other drugs throughout the database. Phase I demonstrated that logistic regression is a capable and generalizable method for providing intuitive and clinically reasonable safety signal scores in situations involving complex polytherapy where simpler non-model-based techniques are not reliable. Phase II focuses on design, prototyping, and full-scale development of a suitable high-performance, multivariate Bayesian logistic regression method; creation of an enhanced version of applicant's WebVDME safety data mining system incorporating a new regression-based computational core; and beta testing the new software with participation by academia, pharmaceutical companies, and FDA. The key Public health benefit is an improved ability to generate and interpret signals of potential drug safety problems, and to prioritize efforts to investigate and evaluate these signals.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.